Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?

Executive Summary

The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be a lasting problem.

You may also be interested in...



FDA Nominee Gottlieb's Recusals Span Clinical Decision Software Firms, Imaging Centers, Drug Makers

FDA Commissioner nominee Scott Gottlieb's many pledges to the US Office of Government Ethics to recuse himself from decisions he might make while serving as head of the agency, cover over 35 outfits that he has worked for, is working for, or has invested in, spanning all types of medical commodities, from advanced imaging centers, to drug firms, to clinical decision software specialists and trial designers.

FDA Nominee Gottlieb's Recusals Span Clinical Decision Software Firms, Imaging Centers, Drug Makers

FDA Commissioner nominee Scott Gottlieb's many pledges to the US Office of Government Ethics to recuse himself from decisions he might make while serving as head of the agency, cover over 35 outfits that he has worked for, is working for, or has invested in, spanning all types of medical commodities, from advanced imaging centers, to drug firms, to clinical decision software specialists and trial designers.

Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process

Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel